Role of PRAS40 in Akt and mTOR signaling in health and disease. (Q37987085)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Role of PRAS40 in Akt and mTOR signaling in health and disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Claudia Wiza

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

21 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Physiology - Endocrinology and Metabolism

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

E1453-60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22354785%20AND%20SRC:MED&resulttype=core&format=json

Two phases of palmitate-induced insulin resistance in skeletal muscle: impaired GLUT4 translocation is followed by a reduced GLUT4 intrinsic activity.

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Large-scale characterization of HeLa cell nuclear phosphoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Discovery of pyrrolopyrimidine inhibitors of Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

High glucose upregulation of early-onset Parkinson's disease protein DJ-1 integrates the PRAS40/TORC1 axis to mesangial cell hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Phosphoproteomic profiling of in vivo signaling in liver by the mammalian target of rapamycin complex 1 (mTORC1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

The binding of PRAS40 to 14-3-3 proteins is not required for activation of mTORC1 signalling by phorbol esters/ERK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Activation of mTOR and RhoA is a major mechanism by which Ceramide 1-phosphate stimulates macrophage proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Regulation of the 14-3-3-binding protein p39 by growth factors and nutrients in rat PC12 pheochromocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Amino acid signaling in TOR activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Identification of a proline-rich Akt substrate as a 14-3-3 binding partner

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

An emerging role of mTOR in lipid biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

PRAS40 deregulates apoptosis in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

PRAS40: target or modulator of mTORC1 signalling and insulin action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Tissue-specific coupling between insulin/IGF and TORC1 signaling via PRAS40 in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Modulation of proline-rich akt substrate survival signaling pathways by oxidative stress in mouse brains after transient focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Neuroprotective role of a proline-rich Akt substrate in apoptotic neuronal cell death after stroke: relationships with nerve growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Activation of the cardiac mTOR/p70(S6K) pathway by leucine requires PDK1 and correlates with PRAS40 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Lobe and Serrate are required for cell survival during early eye development in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Critical nodes in signalling pathways: insights into insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Reduction of Lobe leads to TORC1 hypoactivation that induces ectopic Jak/STAT signaling to impair Drosophila eye development

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Structure of the human mTOR complex I and its implications for rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Increased expression of a proline-rich Akt substrate (PRAS40) in human copper/zinc-superoxide dismutase transgenic rats protects motor neurons from death after spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00660.2011